Aiib Fx 42.25% Dec24 Try (2822316) News

Form 8-K - Current report

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in...

Viking Therapeutics to Participate at Upcoming Investor Conferences

Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire SAN DIEGO, May 30, 2024 SAN...

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 - Securities to be offered to employees in employee benefit plans

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire SAN...

U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading

U.S. index futures are showing mixed results in pre-market trading this Wednesday, as investors assess the...

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 PR Newswire SAN...

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock PR Newswire SAN DIEGO...